VBIO Vitality Biopharma Inc

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

Vitality Biopharma Co-Founder Dr. Avtar Dhillon Resigns from Board of Directors

LOS ANGELES, April 25, 2019 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that Dr. Avtar Dhillon has decided to resign from its board of directors. 

Dr. Dhillon was a co-founder of the Company along with Vitality’s current CEO Robert Brooke, and he has previously served as its Chairman and as a Director.  He departs to focus on other professional interests including a senior management role with a licensed medical cannabis producer in Canada.

“It has been a pleasure for me to have been a co-founder of Vitality and to help build it to its current stage. Under its new leadership, including a strong board and management, I’m leaving the company in great hands,” said Dr. Dhillon.  He added that, “Given the Company’s recent financing and the continued progress of its team, I remain very excited about Vitality’s growth potential.”  

Vitality’s Chairman of the Board Edward Feighan accepted the resignation and stated, “Dr. Dhillon’s service on our Board has been extremely valuable and insightful.  I know that I share the sentiments of our Board and senior management to state that his guidance and support have been critical to our success to date.  The entire Vitality family is grateful for his leadership, and wishes him much success with his current and future ventures.”

About Vitality Biopharma (Ticker: VBIO)

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. The Company’s operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence.  For more information, visit: . Follow us on , and .               

Contact                                                                                              

Vitality Biopharma

Investor Relations

                                                                                

1-530-231-7800

EN
25/04/2019

Underlying

VBIOVitality Biopharma Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vitality Biopharma Inc

 PRESS RELEASE
Free
VBIO Vitality Biopha...

Vitality Biopharma Adopts New Name – Malachite Innovations, Inc.

Vitality Biopharma Adopts New Name – Malachite Innovations, Inc. New Corporate Name Reflects Company’s Expanded Business Strategy, Corporate Restructuring, and Other Corporate Changes CLEVELAND, Ohio, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. has changed its name to MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (pronounced “mal-a-kite”) following a corporate restructuring intended to reflect the Company’s expanded business strategy and corporate rebranding. The Company also announced other corporate changes in support of the Company’s new strategic plan to create long-t...

October 12, 2021 1 EN
 PRESS RELEASE
Free
VBIO Vitality Biopha...

Vitality Biopharma Announces Effective S-1 Registration Statement and ...

Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility CLEVELAND, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Securities and Exchange Commission has declared the Company’s Form S-1 registration statement effective. The registration statement was filed pursuant to the Securities Purchase Agreement, dated as of August 19, 2021, entered into by the Company with Trito...

September 3, 2021 1 EN
 PRESS RELEASE
Free
VBIO Vitality Biopha...

Vitality Biopharma Enters Into $5 Million Equity Line Financing Relati...

Vitality Biopharma Enters Into $5 Million Equity Line Financing Relationship With Institutional Investor CLEVELAND, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the Company had entered into a definitive agreement with an institutional investor for a $5,000,000 equity line financing. Under the terms of the equity line financing, once the registration statement covering these shares is declared effective, the i...

August 20, 2021 1 EN
 PRESS RELEASE
Free
VBIO Vitality Biopha...

FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prod...

FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic powers of cannabinoids, today announced that the U.S. Food and Drug Administration (“FDA”) granted Orphan Drug Designation to its glycosylated cannabinoid prodrug VBX-100 for the treatment of pediatric ulcerative colitis. “The FDA’s granting of Orphan Drug Designation for VBX-100, our leading glycosylated cannabinoid f...

August 10, 2021 1 EN
 PRESS RELEASE
Free
VBIO Vitality Biopha...

Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Altern...

Vitality Biopharma Retains DelMorgan & Co. to Explore Strategic Alternatives CLEVELAND, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”), a drug development company dedicated to unlocking the unique therapeutic powers of cannabinoids, today announced that it has retained DelMorgan & Co., an internationally recognized investment banking firm, to advise Vitality on its strategic alternatives, including potential financings, asset divestitures or strategic partnerships. “We are thrilled to be working with DelMorgan to evaluate strategic...

September 25, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch